Evidence map›Paper›PMID 31407831›Full record

ArticleGenetic epidemiology2019

Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.

Lennox Din, Mohammad Sheikh, Nikitha Kosaraju, Karin Ekstrom Smedby, Sasha Bernatsky, Sonja I Berndt, Christine F Skibola, Alexandra Nieters, Sophia Wang, James D McKay and 82 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genetic epidemiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 4 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. CD5Discover oncology · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

92 authors at 20 institutions in 15 countries.

Lennox DinCollege of Medicine, California Northstate University, Elk Grove, California.
Mohammad SheikhCollege of Medicine, California Northstate University, Elk Grove, California.
Nikitha KosarajuCenter for Neuroengineering and Therapeutics, Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Karin Ekstrom SmedbyDivision of Clinical Epidemiology, Department of Medicine, Karolinska Institutet, Solna, Sweden.
Sasha BernatskyFaculty of Medicine, McGill University, Montreal, Canada.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Christine F SkibolaSchool of Medicine, Emory University, Atlanta, Georgia.
Alexandra NietersCentre of Chronic Immunodeficiency, University Medical Centre Freiburg, Freiburg im Breisgau, Germany.
Sophia WangDepartment of Population Sciences, City of Hope and the Beckman Research Institute, Duarte, California.
James D McKayInternational Agency for Research on Cancer, Lyon, France.
Pierluigi CoccoDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Sardinia, Italy.
Marc MaynadiéThe University of Burgundy-Franche-Comté and CHU Dijon Bourgogne, Registre des Hémopathies Malignes de Côte d'Or, INSERM U1231, Dijon, France.
Lenka ForetováDepartment of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Anthony StainesSchool of Nursing and Human Science, Dublin City University, Dublin, Ireland.
Thomas M MackNorris Comprehensive Cancer Center and Hospital, University of Southern California, Los Angeles, California.
Silvia de SanjoséReproductive Health Global Program PATH, School of Public Health, University of Washington, Seattle, Washington, USA.
Timothy J VyseDepartment of Medical and Molecular Genetics, King's College London, London, England.
Leonid PadyukovDivision of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Alain MonnereauCenter of Research in Epidemiology and Statistics, Sorbonne (CRESS), Epidemiology of Childhood and Adolescent Cancer Group, INSERM, Paris, France.
Alan A ArslanDepartment of Obstetrics and Gynecology, Department of Population Health, Department of Environmental Medicine, NYU School of Medicine, New York, New York.
Amy MooreDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Angela R Brooks-WilsonCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada.
Anne J NovakDepartment of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Bengt GlimeliusDepartment of Immunology, Genetics, and Pathology, Uppsala Universitet, Uppsala, Sweden.
Brenda M BirmannChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Brian K LinkInternal Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa.
Carolyn StewartMemorial Sloan Kettering Cancer Center, New York, New York.
Claire M VajdicCentre for Big Data Research in Health, University of New South Wales, Kensington, Australia.
Corinne HaiounLymphoid Malignancies Unit, Henri Mondor Hospital, University Paris-Est Créteil (UPEC), Paris, France.
Corrado MagnaniMedicina Traslazionale, Università del Piemonte Orientale, Vercelli, Italy.
David V ContiDepartment of Preventive Medicine, University of Southern California, Los Angeles, Califonia.
David G CoxCentre de Recherche en Cancerologie de Lyon, Lyon, France.
Delphine CasabonneUnit of Infections and Cancer, Cancer Epidemiology Research Programme, Institut Català d' Oncologia, (IDIBELL), Barcelona, Spain.
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Eleanor KaneDepartment of Health Sciences, University of York, York, England.
Eve RomanDepartment of Health Sciences, University of York, York, England.
Giacomo MuziDepartment of Medicine, Universita degli Studi di Perugia, Perugia, Italy.
Gilles SallesHematology Department, Centre Hospitalier Universitaire de Lyon, Lyon, France.
Graham G GilesCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia.
Hans-Olov AdamiDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Hervé GhesquièresHematology Department, Centre Hospitalier Universitaire de Lyon, Lyon, France.
Immaculata De VivoChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Jacqueline ClavelDepartment of Environmental Epidemiology of Cancers, INSERM, Paris, France.
James R CerhanDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-7482-178X
John J SpinelliPopulation Oncology, British Columbia Cancer Agency, Vancouver, Canada.
Jonathan HofmannDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Joseph VijaiMemorial Sloan Kettering Cancer Center, New York, New York.
Karen CurtinDepartment of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake, Utah.
Karen H CostenbaderChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Kenan OnelDepartment of Pediatrics, University of Chicago, Chicago, Illinois.
Kenneth OffitDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Lauren R TerasBehavioral and Epidemiology Research Group, American Cancer Society, Atlanta, Georgia.
Lindsay MortonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Lucia CondeBill Lyons Informatics Centre, UCL Cancer Institute, University College London Cancer Institute, London, England.
Lucia MiligiEnvironmental and Occupational Epidemiology Branch, Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research Prevention and Clinical Network (ISPRO), Florence, Florence, Italy.
Mads MelbyeDepartment of Epidemiology Research, Statens Serum Institut, København, Denmark.
Maria Grazia EnnasSchool of Biomedical Sciences, University of Calgary, Calgary, Canada.
Mark LiebowDepartment of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Mark P PurdueDivision of Cancer Biology, National Cancer Institute, Bethesda, Maryland.
Martha GlennDepartment of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake, Utah.
Melissa C SoutheyDepartment of Clinical Pathology, Genetic Epidemiology Laboratory, University of Melbourne, Melbourne, Australia.
Morris DinCalifornia State University, Sacramento, Califonia.
Nathaniel RothmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Nicola J CampDepartment of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake, Utah.
Nicole Wong DooClinical School, Concord Hospital, University of Sydney, Sydney, Australia.
Nikolaus BeckerDivision of Cancer Epidemiology, Deutsches Krebsforschungszentrum, Heidelberg, Germany.
Nisha PradhanMemorial Sloan Kettering Cancer Center, New York, New York.
Paige M BracciDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
Paolo BoffettaTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Paolo VineisSchool of Public Health, Imperial College London, London, England.
Paul BrennanInternational Agency for Research on Cancer, Lyon, France.
Peter KraftDepartments of Epidemiology and Biostatistics, Harvard School of Public Health, Boston, Massachusetts.
Qing LanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Richard K SeversonDepartment of Family Medicine and Public Health Sciences, Wayne State University, Detroit, Michigan.
Roel C H VermeulenDivision of Environmental Epidemiology, Institute for Risk Assessment Science, Utrecht University, Utrecht, Netherlands.
Roger L MilneCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia.
Rudolph KaaksDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
Ruth C TravisCancer Epidemiology Unit, University of Oxford, Oxford, England.
Stephanie J WeinsteinDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Stephen M AnsellDepartment of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Susan L SlagerDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Tongzhang ZhengSchool of Public Health, Brown University, Providence, Rhode Island.
Yawei ZhangDepartment of Environmental Health Sciences, Yale School of Public Health, New Haven, Connecticut.
Yolanda BenaventeUnit of Infections and Cancer, Cancer Epidemiology Research Programme, Institut Català d' Oncologia, (IDIBELL), Barcelona, Spain.
Zachary TaubUniversity of California, Davis, California.
Lohith MadireddyDepartment of Neurology, University of California, San Francisco, California.
Pierre-Antoine GourraudCentre de Recherche en Transplantation et Immunologie, Université de Nantes, Centre Hospitalier Universitaire (CHU, INSERM), Nantes, France.
Jorge R OksenbergDepartment of Neurology, University of California, San Francisco, California.
Wendy CozenDepartments of Preventive Medicine and Pathology, Norris Comprehensive Cancer Center and Hospital, University of Southern California, Los Angeles, California.
Henrik HjalgrimDepartment of Epidemiology Research, Statens Serum Institut, København, Denmark.
Pouya KhankhanianCenter for Neuroengineering and Therapeutics, Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-8075-4176
National Cancer Institute · USInserm · FRMemorial Sloan Kettering Cancer Center · USBrigham and Women's Hospital · USMayo Clinic · USThe University of Melbourne · AUUniversity of California, San Francisco · USUniversity of Southern California · USUniversity of Utah · USBC Cancer Agency · CACalifornia Northstate University · USCentre international de recherche sur le cancer · FRGerman Cancer Research Center · DEHôpital Lyon Sud · FRInstitut d'Investigació Biomédica de Bellvitge · ESKarolinska Institutet · SEMayo Clinic in Florida · USStatens Serum Institut · DKUniversity of York · GBAmerican Cancer Society · US

Funding

HRS Yrs29-34: Y33 SSA CoFundingU01AG009740 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jessica Faul, KENNETH M LANGA · 1990 to 2026
$555.8M
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1M
Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8M
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0M
The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI LENTZ, STEVEN R · 2002 to 2021
$45.7M
Washington University Institute of Clinical and Translational Sciences (UL1)UL1RR024992 · NCRR · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2007 to 2011
$45.4M
Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
CCR NIH HHS N01 RC037004Medical Research Council G0700061Medical Research Council G1001799Medical Research Council MR/N01104X/1Medical Research Council MR/N01104X/2NCATS NIH HHS UL1 TR000135NCATS NIH HHS UL1 TR001863NCATS NIH HHS UL1 TR002345NCCDPHP CDC HHS U58 DP000807NCI NIH HHS CA62006NCI NIH HHS HHSN261201000006CNCI NIH HHS HHSN261201000026CNCI NIH HHS HHSN261201000034CNCI NIH HHS HHSN261201000035CNCI NIH HHS HHSN261201000035INCI NIH HHS HHSN261201000140CNCI NIH HHS K08 CA134919NCI NIH HHS N01 CO012400NCI NIH HHS N01 PC065064NCI NIH HHS N01 PC067008NCI NIH HHS N01 PC067010NCI NIH HHS P01 CA087969NCI NIH HHS P01 CA196569NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016087NCI NIH HHS P30 CA042014NCI NIH HHS P30 CA086862NCI NIH HHS P30 CA15083NCI NIH HHS P50 CA093459NCI NIH HHS P50 CA097007NCI NIH HHS P50 CA097274NCI NIH HHS R01 CA045614NCI NIH HHS R01 CA049449NCI NIH HHS R01 CA062006NCI NIH HHS R01 CA087014NCI NIH HHS R01 CA092153NCI NIH HHS R01 CA098122NCI NIH HHS R01 CA098661NCI NIH HHS R01 CA104021NCI NIH HHS R01 CA122663NCI NIH HHS R01 CA129539NCI NIH HHS R01 CA133996NCI NIH HHS R01 CA134674NCI NIH HHS R01 CA134958NCI NIH HHS R01 CA140561NCI NIH HHS R01 CA148690NCI NIH HHS R01 CA149445NCI NIH HHS R01 CA154643NCI NIH HHS R01 CA200703NCI NIH HHS R01 CA201407NCI NIH HHS R03 CA150037NCI NIH HHS U01 CA049449NCI NIH HHS U01 CA118444NCI NIH HHS U01 CA167552NCI NIH HHS U01 CA195568NCI NIH HHS UM1 CA167552NCI NIH HHS UM1 CA186107NCRR NIH HHS C06 RR020092NCRR NIH HHS UL1 RR024992NHGRI NIH HHS T32 HG009495NHGRI NIH HHS U01 HG004446NHGRI NIH HHS U01 HG007033NHLBI NIH HHS HHSN268201100001INHLBI NIH HHS HHSN268201100002INHLBI NIH HHS HHSN268201100003INHLBI NIH HHS HHSN268201100004INHLBI NIH HHS HHSN268201100046CNHLBI NIH HHS R37 HL039693NIAID NIH HHS R01 AI076544NIA NIH HHS HHSN271201100004CNIA NIH HHS RC2 AG036495NIA NIH HHS RC4 AG039029NIA NIH HHS U01 AG009740NIEHS NIH HHS ES000260NIEHS NIH HHS P30 ES000260NIEHS NIH HHS R01 ES011740NIEHS NIH HHS R01 ES016813NIEHS NIH HHS R21 ES024844NIH HHS AI076544NIH HHS CA098122, and CA134958NIH HHS CA104021NIH HHS CA118444NIH HHS CA148690NIH HHS CA149445NIH HHS CA186107NIH HHS CA49449NIH HHS CA87969NIH HHS CA92153NIH HHS CA97274NIH HHS K08CA134919NIH HHS NO1-CO-12400NIH HHS NS032830NIH HHS NS049477NIH HHS NS049510NIH HHS NS067305NIH HHS NS19142NIH HHS NS26799NIH HHS NS43559NIH HHS R01CA134674NIH HHS RR020092NIH HHS RR024992 and K23N/S048869NINDS NIH HHS K23 NS048869NINDS NIH HHS R01 NS026799NINDS NIH HHS R01 NS032830NINDS NIH HHS R01 NS043559NINDS NIH HHS R01 NS049477NINDS NIH HHS R01 NS049510NINDS NIH HHS R01 NS067305Wellcome TrustWellcome Trust 075491/Z/04/Z, and 068545/Z/02Wellcome Trust 085475/B/08/ZWellcome Trust 085475/Z/08/ZWHI NIH HHS HHSN268201100001CWHI NIH HHS HHSN268201100002CWHI NIH HHS HHSN268201100003CWHI NIH HHS HHSN268201100004CWorld Health Organization 001
6 · The paper itself

Abstract

Epidemiologic studies show an increased risk of non-Hodgkin lymphoma (NHL) in patients with autoimmune disease (AD), due to a combination of shared environmental factors and/or genetic factors, or a causative cascade: chronic inflammation/antigen-stimulation in one disease leads to another. Here we assess shared genetic risk in genome-wide-association-studies (GWAS). Secondary analysis of GWAS of NHL subtypes (chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma) and ADs (rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis). Shared genetic risk was assessed by (a) description of regional genetic of overlap, (b) polygenic risk score (PRS), (c)"diseasome", (d)meta-analysis. Descriptive analysis revealed few shared genetic factors between each AD and each NHL subtype. The PRS of ADs were not increased in NHL patients (nor vice versa). In the diseasome, NHLs shared more genetic etiology with ADs than solid cancers (p = .0041). A meta-analysis (combing AD with NHL) implicated genes of apoptosis and telomere length. This GWAS-based analysis four NHL subtypes and three ADs revealed few weakly-associated shared loci, explaining little total risk. This suggests common genetic variation, as assessed by GWAS in these sample sizes, may not be the primary explanation for the link between these ADs and NHLs.

Indexed as

Genetic Predisposition to DiseaseAllelesAutoimmune DiseasesFemaleHLA AntigensHumansLymphoma, Non-HodgkinMaleMiddle AgedMultifactorial InheritancePolymorphism, Single NucleotideRisk FactorsHLA Antigensautoimmune diseasegenome-wide association studymeta-analysisnon-Hodgkin lymphoma

Identifiers

PMID31407831
PMCPMC6763347
OpenAlexW2968755345

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.